Trefoil Therapeutics, Inc. Report issue

For profit Phase 2
Founded: San Diego CA United States (2014)

Organization Overview

First Clinical Trial
2020
NCT04520321
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Trefoil Therapeutics | Trefoil Therapeutics.com | Trefoil Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

tthx1114 (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Corneal Dystrophies, Hereditary (Phase 2)

Fuchs' Endothelial Dystrophy (Phase 2)

Iridocorneal Endothelial Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 1